Abstract
Summary
1. A new anticoagulant, Dipaxin (diphenylacetyl-1,3 -indandione), has been studied in man. This agent induces an effective hypoprothrombinemia in single doses of as little as 4 mg. It appears to be more potent on a weight basis than any other known agent. After single doses of 20 mg a marked hypoprothrombinemia was usually evident in 48 hours which persisted from 6 to 10 days. Its effects were usually reproducible and predictable. 2, The drug was successfully administered therapeutically. The recommended starting dose is about 20 mg. A schedule of dosages is given. The maintenance of adequate clinical hypoprothrombinemia was obtained with daily doses of 2 to 4 mg. Hypoprothrombinemia was readily overcome with vit. K, the natural vitamin being more effective than the synthetic. No bleeding or other toxic phenomena were encountered. 3. The advantages and disadvantages of Dipaxin as a clinically useful hypoprothrombinemic anticoagulant are briefly discussed.
Get full access to this article
View all access options for this article.